organization of HIV researchers and specialists, and funds research fellowships for junior investigators in infectious diseases. With the support of a CDC grant IDSA entertains a listserv for infectious disease physicians called Emerging Infections Network. It allows members to check on unusual clinical events, a potentially emerging infectious disease by connecting members to the CDC and other public health investigators and it is capable of queries and surveys. Support for the Prevention and Public Health Fund On November 3, 2017, the U.S. House passed a bill, H.R. 3922 (the "CHAMPIONING Healthy Kids Act") that cuts $6.35 billion from the Prevention and Public Health Fund (PPHF). Paul Auwaerter, then-president of IDSA, said that the cut would hurt both public health and national security. The PPHF fund comprises over 12 percent of the budget of the Centers for Disease Control and Prevention (CDC). Auwaerter said, "…a significant cut to the fund will have a very troubling impact on CDC efforts to prevent infections and respond to outbreaks in communities and health care settings." The PPHF was created under the Affordable Care Act to fund programs for prevention and public health activities. The fund supports programs that prevent, monitor, and respond to infectious diseases, including immunization programs; responses to outbreaks of "vaccine-preventable illnesses"; adult immunization registries; managing emerging health issues such as food-borne infection outbreaks and waterborne diseases; and programs that support Alzheimer's, diabetes, heart disease, and stroke prevention strategies. Several organizations such as the American Heart Association and American Lung Association joined the IDSA in opposing the cuts. Antimicrobial Resistance (10 x '20) Initiatives The World Health Organization has identified antimicrobial resistance as one of the three greatest threats to human health. IDSA has identified antimicrobial resistance as a priority for the organization. In 2010, IDSA launched the 10 x '20 Initiative, which seeks a global commitment to create an antibiotic research and development enterprise powerful enough to produce 10 new systemic antibiotics by the year 2020. The initiative was launched as a response to the growing problem of antibiotic resistance and the lack of development of new antibiotics. According to IDSA, new antibiotic development has slowed to a standstill due to market failure and regulatory disincentives. Antibiotics aren't as profitable as other drugs (e.g., drugs to treat chronic conditions such as diabetes or asthma, which patients take for years). Also, the U.S. Food and Drug Administration (FDA) has long delayed publishing